Stephen H Thorne

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 11

Top Topics

Transforming Growth Factor

Immune Response

Top Venues

Cancer immunology research

The Journal of experimental medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Lulu Shao, Rashmi Srivastava, Greg M Delgoffe, Stephen H Thorne, Saumendra N Sarkar
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance. Cancer immunology research 12 (6) (2024)
Lulu Shao, Rashmi Srivastava, Greg M Delgoffe, Stephen H Thorne, Saumendra N Sarkar
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T cells and Promotes Tumor Clearance. Cancer immunology research (2024)
Lulu Shao, Rashmi Srivastava, Greg M Delgoffe, Stephen H Thorne, Saumendra N Sarkar
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance. Cancer immunology research 12 (6) (2024)
Lulu Shao, Rashmi Srivastava, Greg M Delgoffe, Stephen H Thorne, Saumendra N Sarkar
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T cells and Promotes Tumor Clearance. Cancer immunology research (2024)
Lulu Shao, Rashmi Srivastava, Greg M Delgoffe, Stephen H Thorne, Saumendra N Sarkar
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T cells and Promotes Tumor Clearance. Cancer immunology research (2024)
Lulu Shao, Rashmi Srivastava, Greg M Delgoffe, Stephen H Thorne, Saumendra N Sarkar
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance. Cancer immunology research 12 (6) (2024)
Lulu Shao, Rashmi Srivastava, Greg M Delgoffe, Stephen H Thorne, Saumendra N Sarkar
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance. Cancer immunology research 12 (6) (2024)
Lulu Shao, Rashmi Srivastava, Greg M Delgoffe, Stephen H Thorne, Saumendra N Sarkar
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance. Cancer immunology research 12 (6) (2024)
Lulu Shao, Rashmi Srivastava, Greg M Delgoffe, Stephen H Thorne, Saumendra N Sarkar
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance. Cancer immunology research 12 (6) (2024)
Lulu Shao, Rashmi Srivastava, Greg M Delgoffe, Stephen H Thorne, Saumendra N Sarkar
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance. Cancer immunology research 12 (6) (2024)
Kristin DePeaux, Dayana B Rivadeneira, Konstantinos Lontos, Victoria G Dean, William G Gunn, McLane J Watson, Tianhong Yao, Drew Wilfahrt, Cynthia S Hinck, Lukasz Wieteska, Stephen H Thorne, Andrew P Hinck, Greg M Delgoffe
An oncolytic virus-delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment. The Journal of experimental medicine 220 (10) (2023)